Background: Urticarial vasculitis (UV) is a rare type of leukocytoclastic vasculitis characterized by
INTRODUCTION
Urticarial vasculitis (UV) is a small vessel vasculitis characterized by long lasting urticarial skin lesions combined with the histopathological finding of leukocytoclastic vasculitis.
1,2 The clinical picture of UV, or "aemorrhagic urticaria" as it used to be called, was first described in 2 male patients by Wills and Lond in 1890. 3 In 1956, the histopathological finding of vasculitis was reported in 2 patients with urticaria.
4 UV is a rare skin disorder. 5 The worldwide prevalence of UV is unknown. As little as 2% and up to 27% of patients who initially present with urticaria have been reported to have UV.
6-9 UV tends to have a chronic course. 2 The median age of disease onset and age at diagnosis is 35-51 years, with more female patients affected.
10-15
Although most UV cases are of unknown cause, UV can be associated with drugs, infections, autoimmune and autoinflammatory diseases, or malignancy. 2, 6, 11 The clinical spectrum is wide and varies from a mild urticarial rash to severe disease with systemic manifestations including fever, fatigue, pulmonary, gastrointestinal, renal, eye, and joint involvement. 12, 13, 16, 17 UV skin lesions often resolve with hyperpigmentation, and they are frequently associated with burning sensations or pain. 12, 13, 16 Besides recurrent wheals, which persist in most cases of more than 24 hours to up to several days, UV patients can present with intermittent angioedema.
12
Based on blood complement levels (C3, C4), UV is divided into normocomplementemic (normocomplementemic urticarial vasculitis, NUV) and hypocomplementemic subsets including hypocomplementemic urticarial vasculitis (HUV) and hypocomplementemic urticarial vasculitis syndrome (HUVS, McDuffie syndrome 18 ). Most UV patients present with NUV (approx. 80%), whereas HUV/HUVS affects 9-21% of UV patients.
6,10,11
Systemic symptoms and underlying diseases are more frequent in patients with hypocomplementemic subsets of UV. 6, 11 In HUV/HUVS patients, 1-10-year survival rates are higher than 80%.
14 Fatal cases can be associated with underlying disease such as malignancy. Pathophysiologically, UV is held to involve type III hypersensitivity with deposition of antigenantibody complexes and complement factors in the vascular lumen.
19
Activation of the complement system leads to cutaneous neutrophil influx, increase in vascular permeability, and mast cell degranulation with consecutive release of further chemokines and cytokines. 19, 20 The treatment of UV depends on the clinical phenotype, the presence of systemic symptoms and/or underlying diseases. It is often a difficult-totreat condition. Systemic corticosteroids are effective for the treatment of cutaneous symptoms in more than 80% of UV patients, but their longterm use comes with considerable adverse effects.
2
The addition of immunomodulatory/ immunosuppressive drugs can enable corticosteroid tapering and improvement of treatment responses. The anti-Immunoglobulin (Ig) E antibody omalizumab, cyclophosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchicine, hydroxychloroquine, intravenous immunoglobulin, cyclosporine, and nonsteroidal anti-inflammatory drugs have been described to be effective in case reports and small case series, but controlled studies are missing.
2 As of now, no drugs have been approved for the treatment of patients with UV.
Despite the current knowledge of UV, no clinical guidelines, diagnostic criteria or treatment algorithms have been published so far for this disorder.
To help with the development of international consensus-based recommendations for the classification of UV and the diagnostic workup and treatment of patients with UV, we aimed at assessing the current real-life management of UV patients. It is currently unknown which specialists see UV patients and why they are referred to them. Furthermore, we do not know which criteria and diagnostic tests are used to diagnose UV. We also have very little information on which treatments are used and with which outcome. Until now, there are no studies on the worldwide management of UV, and the approaches to the diagnostic workup and treatment of UV patients may differ globally.
To address these unmet needs, we conducted an online survey and examined (a) how UV patients are diagnosed and treated by international specialists including differences in approaches and (b) the greatest challenges in managing UV patients worldwide. In addition, we aimed to identify further unmet needs in the management of patients with UV.
METHODS

Study survey
A web-based questionnaire (Suppl. Fig. 1 ) was designed and circulated among the co-authors and the members of the WINiT: Skin Allergy Committee of the World Allergy Organization (WAO). We then tested the questionnaire in 7 physicians involved in the care of UV patients (n ¼ 4 from Germany, n ¼ 1 from Japan, n ¼ 1 from Russia, n ¼ 1 from Turkey) and revised and finalized the questionnaire based on their feedback. The questionnaire is comprised of 14 questions including 4 single-choice and 10 multiple-choice questions. We assessed demographic data (country of residence, specialty, clinical experience, and type of practice) and data on the management of UV patients (number of UV patients seen per year, establishment of the diagnosis by referring doctor/ survey participant, reasons for referral of UV patients, occurrence of cutaneous symptoms, occurrence of extracutaneous symptoms, diagnostic criteria, diagnostic work-up, comorbidities/ potential causes, treatment options, and greatest challenges in UV management).
Recruitment and dissemination
Distribution of the questionnaire included emails to individuals in the World Allergy Organization (WAO) database, with no restrictions applied to the specialty, affiliation, or nationality of the participants (November 2018 
RESULTS
Demographics of study population
Of the 883 specialist physicians from 92 countries who participated in this study, most resided in Europe (46% 
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The median number of patients with UV seen per year was reported to be 5. Post hoc analyses revealed statistically significantly lower numbers of UV patients seen per year for physicians from North America (NA) as compared to Latin America (LA), Europe (EU), Africa/Middle-East (AME), or
Parameter
Respondents (n ¼ 883) The most frequent reason for referring patients with UV to specialist physicians is to establish the diagnosis "Establish a diagnosis" was the most frequent reason reported by respondents as to why patients with UV were referred to them. Other common reasons for referral of UV patients were treatment initiation and optimization, as well as requests for a second opinion and to perform basic and clinical research ( Table 3) .
As compared to allergists, a higher number of dermatologists reported "treatment initiation"
(50% vs 39%, c2 ¼ 6.374, p ¼ 0.01) or "clinical/ basic research" reasons (18% vs 6%, c2 ¼ 22.335, p < 0.001). The number of university physicians, who reported "establish a diagnosis", "treatment initiation", "second opinion", and "clinical/basic research" as reasons for referral, was higher than the number of non-university or private practice physicians who did this (p < 0.05).
Physicians from North America or Europe more often reported "establish a diagnosis" as the n, UV patients per year P-value Median IQR
Region of residence
Place of work a University clinic (n ¼ 223) 5 2-10 <0.001
Private practice (n ¼ 245) 3 1-6 Most physicians report that wheals, burning of the skin, and residual hyperpigmentation occur in 60-100% of UV patients
More than two-thirds of physicians observed wheals (83%), residual hyperpigmentation (70%), and burning of the skin (69%) in the majority, i.e. 60-100%, of UV patients (Fig. 1) . With respect to systemic symptoms, 43% of physicians reported that most of their UV patients (i.e. 60-100%) have fatigue, asthenia, and/or fever. Thirty-eight (38) percent reported that their patients have musculoskeletal complaints, for example, arthralgia or arthritis. In contrast, only a few physicians, less than 10%, reported that more than 60% of their patients have ocular, pulmonary, kidney, or neurological symptoms (Fig. 2) .
Wheals of longer than 24 hours duration, the results of histological analysis, and postinflammatory hyperpigmentation are the most important features for establishing the diagnosis of UV When asked to select the 3 most important features for establishing the diagnosis of UV, the most frequent ones were wheals of longer than 24 hours duration (72%), the results of histological analysis (63%), and post-inflammatory hyperpigmentation (46%) ( Table 4) .
Physicians residing in North America (74%), dermatologists (79%), and university physicians (75%) more frequently indicated that the results of histological analyses are the most important to establish the diagnosis of UV (p 0.01). Physicians who did not choose histological analysis chose "wheals predominantly >24 h" (80%), "presence of post-inflammatory hyperpigmentation" (55%), and/or "poor response to antihistamines" (42%) as important features for establishing the diagnosis of UV. Many of them were from Africa/Middle-East, non-dermatologists, and worked in a nonuniversity hospital (Table 5 ).
The most common tests ordered in UV patients are complete blood count, erythrocyte sedimentation rate, C-reactive protein, complement components, antinuclear antibodies and skin biopsy
Most physicians reported that they order a complete blood count (95%), C-reactive protein (CRP) (91%), complement components (88%), ESR (88%), antinuclear antibodies (ANA) (84%), a skin biopsy (77%), antithyroid antibodies (75%), and thyroid stimulating hormone (67%) in most of their UV patients, i.e. in 60% or more. Some physicians responded that they order eosinophil cationic Fig. 1 Most physicians report that wheals, residual hyperpigmentation, and burning of the skin occur in most of their UV patients*.
The figure depicts the % of physicians who reported the skin symptoms in up to 60-100% of UV patients (the blue line), in up to 20-40% of UV patients (the green line) and in none of the patients (the red line). *Several responses were allowed from the same respondent peptide (29%), autologous serum skin test (47%), and D-dimer (47%) in some of their UV patients. Two-thirds (73%) of physicians ordered allergy tests in UV patients (Fig. 3) . More dermatologists than allergists performed skin biopsy in the majority, i.e. 60-100%, of UV patients (87% vs 77%, c2 ¼ 5.081, p ¼ 0.024).
UV is considered to be of unknown cause in most patients, and drugs and systemic lupus erythematosus are the most common identifiable causes Nine of 10 physicians (89%; 540/609) reported that they look for underlying causes in their patients with UV. Two of three physicians (67%; 395/ 586) responded that they consider UV to be of unknown cause in most patients. With respect to revealed UV causes, 20% and 18% physicians identified drugs and systemic lupus erythematosus (SLE), respectively, in most patients (Fig. 4) . Professionals who reported that they look for underlying causes of UV had more years of practice as compared to respondents who did not (median: 17 vs 10; p ¼ 0.002).
Many respondents prefer second generation antihistamines and/or corticosteroids as the firstline therapy of UV Two of three (65%) physicians reported that they use a second generation antihistamine (sgAH) in Table 5 . Characteristics of physicians who chose or did not choose histological analysis as an important feature for establishing the diagnosis of UV Fig. 3 The percentages of physicians who performed or ordered different tests for the diagnostic workup in UV patients*. The figure depicts the % of physicians who performed or ordered tests in up to 60-100% of UV patients (the blue line), in up to 20-40% of UV patients (the green line) and in none of the patients (the red line). *Several responses were allowed from the same respondent; TSH: thyroid stimulating hormone; ESR: erythrocyte sedimentation rate; ANA: antinuclear antibodies; ECP: eosinophil cationic protein; ASST: autologous serum skin test; CRP: C-reactive protein standard dose as the first-line therapy in patients with UV. High doses of an antihistamine and corticosteroids were the first-line therapy of 40% and 38% of physicians, respectively. Only 13% of physicians from North America reported that they use corticosteroids as the first-line therapy. Updosing of sgAHs and/or corticosteroids were the most common second-line therapy, cyclosporine and omalizumab the most common third-and fourthline therapy (Fig. 5) .
The greatest perceived challenges in the management of UV are limited efficacy of drugs and absence of clinical guidelines and treatment algorithms
Most physicians indicated that there are many challenges in managing patients with UV. The most commonly reported ones were that the treatments used are of limited efficacy (60%) and have adverse effects (48%) and that there are no clinical guidelines and treatment algorithms (59%) ( Table 6) . 
DISCUSSION
This is the first worldwide research project that assesses personal physician preferences in managing UV patients.
As reported by the almost 900 physicians who participated in this project, UV is a rare disease with only 5 patients seen per physician per year on average. In the literature, UV has been described in 2.7% (n ¼ 21) of 766 patients with cutaneous vasculitis. 15 Although worldwide prevalence and incidence of UV is unknown, a point prevalence and the mean annual incidence rate of HUV/ HUVS per one million Swedish inhabitants was estimated to be 9.5 and 0.7, respectively.
14 After age and sex adjusted to the 2000 US caucasian population, the population-based incidence rate of UV was 0.5 per 100,000 person-years.
22
In UV, as in other inflammatory skin diseases, the management should be aimed at (a) excluding differential diagnoses, primarily chronic spontaneous urticaria (CSU), (b) identifying relevant triggers and/or underlying causes, (c) assessing disease activity, impact, and control, and (d) appropriate treatment.
The most frequent reason for referring patients with UV to specialist physicians is to establish the diagnosis. Wheals of longer than 24 hours duration and residual hyperpigmentation were the most popular clinical features for UV diagnosis reported.
Most physicians observed long-lasting wheals, residual hyperpigmentation and burning of the skin in 60-100% of UV patients (Fig. 6a, b) . Regarding systemic symptoms, many physicians reported constitutional and musculoskeletal complaints in most UV patients. This is in line with the results of previous studies where the most frequent skin and systemic manifestations of UV were urticarial lesions and arthritis/arthralgia, respectively.
14,15
The histopathological evaluation of a lesional skin biopsy is considered the gold standard approach for diagnosing cutaneous vasculitis including UV. 23 However, only 63% of physicians indicated that they perform skin biopsies for UV diagnosis. The international urticaria guideline recommends to perform histologic analyses of a skin biopsy as part of the extended diagnostic programme for the identification of underlying causes or eliciting factors and for ruling out possible differential diagnoses including UV.
24
Importantly, some patients with clinical symptoms of UV, for example, poor response to antihistamines or wheals >24 hours, can have CSU. It is currently unclear why more than onethird of physicians including 37% of allergologists do not do skin biopsies for the diagnostic workup of UV. Our results show that these physicians, instead of basing their diagnosis of UV on a skin biopsy, use persistent wheals, residual hyperpigmentation, and poor response to antihistamines as Most physicians ordered complete blood count, C-reactive protein, complement components, ESR, ANA, antithyroid antibodies, and thyroidstimulating hormone in most patients. Inflammation markers, such as CRP or ESR, can be useful for differential diagnosis between UV and CSU.
Analysis of serum levels of complement components allows distinguishing between NUV and HUV/HUVS. The relevance of antithyroid antibodies, and thyroid-stimulating hormone in UV, is unclear. Reportedly, a higher number of UV patients had elevated antithyroid antibodies as compared with patients with CSU. 25 In a few cases, levothyroxine treatment resulted in improvement or remission of UV in patients with hypothyroidism due to autoimmune thyroid disease.
2,26
Although 89% physicians look for underlying causes of UV, many of them considered UV to be of unknown cause in most patients. The literature supports this notion. In a small proportion of patients, UV appears to be due to drug intake or different systemic diseases, such as SLE, hepatitis C, or malignancy. In a systematic review, we could see comorbid SLE, malignancy, and infection in 11%, 7%, and 6% of UV patients, respectively.
2
Withdrawal of relevant drugs, antiviral treatment of chronic hepatitis C, surgical therapy, or chemotherapy and/or radiation therapy of malignant neoplasms are usually associated with improvement or cure of UV.
2,27
The severity of UV and the occurrence of relapses determine the treatment approach. Most respondents prefer second generation antihistamines and/or corticosteroids as the first-line therapy of UV. We previously reported that antihistamines are not effective in most UV cases. However, H1-antihistamines are safe and can be considered for the treatment of itch in UV patients, in children and/or patients without systemic symptoms. Corticosteroids are the mainstay of UV therapy and are also commonly used as initial therapy in this study and previous reports. 2, 14 In this study, we did not analyze which corticosteroids are used for the treatment of patients with UV. Also, it remains unclear how corticosteroids were dosed and for how long they were used. Corticosteroid dosing differed between previous studies, and long-term administration of corticosteroids can induce dosedependent adverse effects.
Various alternative treatment options have been tried including immunosuppressive therapy and biologicals. For example, more than 10 cases of successful use of omalizumab, a monoclonal antiIgE antibody, in UV patients with none or minimal response to treatment with antihistamines have been reported. 2, [28] [29] [30] Complete remission was achieved in 5 of 6 patients with UV within 7 days after treatment with IL-1b inhibitors. In all but 1 patient, treatment with IL-1b inhibitors allowed discontinuation of corticosteroids. UV relapsed after an IL-1 blocker discontinuation. 31 In another study, canakinumab, a long-acting fully humanized monoclonal anti-IL-1b antibody, was effective in 10 patients with active UV. 32 Other frequently reported treatment modalities include cyclosporine, colchicine, hydroxychloroquine, azathioprine, methotrexate, and dapsone.
The limitations of our study include a possible bias due to selection of participants, the use of an online non-validated questionnaire, and the heterogeneous approach to the UV diagnosis. Moreover, our results on the impact of physician specialty should be interpreted with caution, since allergology, the most common specialty in our study, is a subspecialty, and dermatology is the main specialty in some countries.
Unmet needs
The greatest challenges reported by physicians are the absence of clinical guidelines and treatment algorithms as well as the limited efficacy of available drugs and their adverse effects.
First, there is a need for the proper definition and classification of UV. The recently published update of the nomenclature for cutaneous vasculitis based on the 2012 Revised Chapel Hill Consensus Conference distinguishes HUV/HUVS from NUV, "a skin-limited vasculitis, not accompanied by systemic involvement" with the absence of anti-C1q antibodies.
1 However, this classification does not take into account that some NUV patients have systemic symptoms, and it does not differentiate HUV from HUVS. In addition, clinical and histological criteria of UV should be clarified and developed. For this, further specialists such as dermatohistopathologists should be involved.
Second, there is a need for easy-to-perform, cost-effective, and noninvasive tests for differentiating UV from urticaria. 33 For example, Suh et al. showed that dermoscopic red or purpuric dots/ globules and a purple-brown background may be useful distinguishing dermoscopic features of UV and can help in differentiating early UV from early common urticaria lesions.
34
Further prospective studies should assess whether these dermoscopic signs correlate with clinical symptoms and skin biopsy results. The delay in diagnosis and the rate of misdiagnosis in patients with UV are currently unknown but must be expected to be long and high, respectively. The development and availability of better diagnostic tests can help to change this.
Third, no tools for assessing disease activity, impact, and control of UV exist so far.
Although not yet validated, the UV activity score (UVAS) for patient daily self-assessment may be promising tool for assessing UV activity/severity. 32 It includes 5 subscales corresponding to the 5 key symptoms of UV: wheals, burning/pruritus, residual skin pigmentation, joint pain, and general symptoms. UVAS scores range from 0 to 10 per day (0 ¼ none; 10 ¼ very severe).
Fourth, prognostic factors of UV duration and severity should be evaluated. Serum, histologic, and immunopathologic markers should be assessed as predictors of response to treatment.
Finally, no drugs have been approved for the treatment of patients with UV. Prospective studies that investigate new, effective, and safe drugs for the treatment of UV are warranted. Together with the development of a stepwise algorithm of treatment of UV, this will improve the management of UV in everyday clinical practice.
CONCLUSION
In summary, UV is a rare but challenging disease worldwide. Many physicians do not perform skin biopsy, a gold standard for UV diagnosis. This may lead to delays in diagnosis and misdiagnoses, for example, as chronic spontaneous urticaria, and to inadequate treatment. Other pitfalls and challenges in the management of UV include the limited efficacy and safety of treatments and the absence of clinical guidelines and treatment algorithms. These unmet needs should be addressed by further research and with future initiatives. 
